human myelin basic protein (MBP). MBP8298 has been developed for the treatment o

[Guest guest]

Press ReleaseSource BioMS Medical Corp.

BioMS Medical Provides Multiple Sclerosis Trial Update

Tuesday October 26, 7:00 am ET

- Dr. Mark Freedman announced as Lead Investigator -

TSX: MS

EDMONTON, Oct. 26 /CNW/ - BioMS Medical Corp (TSX: MS - News), a

leading developer in the treatment of multiple sclerosis (MS), is

pleased to announce Dr. Mark Freedman, Professor of Neurology at

the

University of Ottawa and Director of the Multiple Sclerosis

Research Clinic at the Ottawa Hospital, as lead investigator for

the

Company's pivotal Phase

II/III clinical trial of its lead drug MBP8298.

" I am pleased to play a key role in one of the only later-stage

clinical trials assessing new therapies for secondary progressive

multiple sclerosis, a form of the disease for which there are few

approved therapies, " said Dr. Freedman. " This trial will assess the

impact of this drug on disease progression and further our

understanding of its underlying immunology. "

Dr. Freedman, B.Sc. M.Sc. M.D. CSPQ FAAN FRCPC, earned his medical

degree at the University of Toronto, and performed post graduate

training at the University of Toronto, Queen Square (London, UK),

McGill and the Weizmann Institute of Science (Israel). He has

published more than 100 papers, book chapters and reviews on MS. Dr.

Freedman is also a

Fellow of the American Academy of Neurology, serves on the medical

advisory committee for the MS Society of Canada and is a member of

the

clinical trial group for the National MS Society (USA). As Director

of the Multiple Sclerosis Research Clinic at the Ottawa Hospital,

he

operates a large and successful MS research unit with approximately

3000 patients.

" The interest in our trial amongst other leading MS clinicians in

Canada has been very positive, and enrollment of patients is

targeted

to commence soon at a number of sites, " said Giese, President

of BioMS Medical. " Dr. Freedman's leadership role in our trial is

supported by his past 20 years of experience in the clinical

development of the current major MS

therapies. "

The trial, approved by Health Canada on June 8, 2004, will enroll up

to 553 patients and is designed to evaluate the efficacy and safety

of MBP8298 in patients with secondary progressive MS. The Company

also intends to seek regulatory approval for the trial outside of

Canada to enroll patients on an international basis.

About BioMS Medical Corp.

-------------------------

BioMS Medical Corp. is a biotechnology company dedicated to the

development and commercialization of innovative therapies. BioMS

Medical's patented MBP8298 technology for the treatment of multiple

sclerosis has undergone Phase I and II human clinical trials and has

recently been approved to enter into a pivotal Phase II/III clinical

trial. In addition, the Company has a platform technology, HYC750,

involving a method for the potential mobilization of stem cells and

neutrophils for the treatment of cancer therapy related

side-effects,

as well as an interest in BioCyDex, a private company developing

platform drug and gene delivery and imaging technology.

BioMS trades on the Toronto St

http://www.biomsmedical.com/MBP8298info.asp

MBP8298

Product Information

MBP8298 is a synthetic peptide that consists of 17 amino acids linked

in a sequence identical to that of a portion of human myelin basic

protein (MBP). MBP8298 has been developed for the treatment of

multiple sclerosis (MS), and is based on over 26 years of research.

MS is generally considered an autoimmune disease, caused by immune

attack against normal components of the central nervous system. The

specificity of the immune attack at the molecular level is determined

in each case by the HLA type of the individual patient, and HLA type

is known to be one factor that contributes to susceptibility to MS.

The MBP8298 synthetic peptide is a molecular replicate of the site of

attack that is dominant in MS patients with HLA haplotypes DR-2 or

DR-4. These HLA types are found in 65-75% of all MS patients.

The apparent mechanism of action of MBP8298 is the induction or

restoration of immunological tolerance with respect to ongoing immune

attack at this molecular site. High doses of antigen delivered

periodically by the intravenous route are expected to suppress immune

responses to the administered substance. The potential benefit of

MBP8298 for any individual patient is therefore expected to be

related

to the extent to which his or her disease process is dominated by

autoimmune attack at the site represented by this synthetic peptide,

and a phase II clinical trial has statistically significant clinical

benefit in patients with HLA haplotypes DR-2 or DR